NCT04915248 2025-12-24
FIL_DALYA
Fondazione Italiana Linfomi - ETS
Phase 2 Recruiting
Clinical Trials
11 trialsNCT06827860 2025-12-18
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT03734198 2025-11-26
IDA53
French Innovative Leukemia Organisation
Phase 2 Active not recruiting
NCT04176718 2025-10-07
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Massachusetts General Hospital
Phase 2 Recruiting
NCT07018050 2025-09-22
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT03450057 2024-03-29
DARE
Hellenic Society of Hematology
Phase 2 Completed
NCT03679624 2023-10-23
Daratumumab Plus Ibrutinib in Patients With WaldenstrÓ§m's Macroglobulinemia
Weill Medical College of Cornell University
Phase 2 Terminated
NCT02807454 2023-02-21
FUSIONMM-003
Celgene
Phase 2 Terminated
NCT03697629 2022-02-15
A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
Canadian Myeloma Research Group
Phase 2 Completed
NCT03000452 2018-10-16
FUSION-MM-005
Celgene
Phase 2 Completed
NCT03143036 2018-06-07
Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma
National University Hospital, Singapore
Phase 2 Unknown